Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

(Neutral)

(Positive)

Key Terms

vitrectomy medical

Vitrectomy is a surgical procedure that removes the eye’s clear, gel-like substance (the vitreous) to treat problems such as bleeding, retinal tears, or detached tissue. Think of it like removing and replacing a cloudy windowpane or the fluid inside a camera to restore a clear picture. Investors care because the procedure drives demand for surgical instruments, implants, drugs and hospital services and its prevalence, cost and reimbursement shape revenue and regulatory risk for medical device and healthcare companies.

adaptive fluidics technical

Adaptive fluidics is a technology that automatically adjusts the flow, pressure, or volume of liquids in medical devices in real time to match a patient’s changing needs, like a smart faucet that senses and changes water speed. For investors, it matters because it can improve safety and efficiency, reduce waste and complications, and make a device more competitive or easier to clear with regulators—factors that can affect sales, margins, and liability risk.

intraocular pressure (iop) medical

Intraocular pressure (IOP) is the fluid pressure inside the eye, like the air pressure inside a tire that keeps the eye’s shape and function stable. IOP matters to investors because persistently high pressure is the main risk factor for glaucoma and other vision problems, so IOP readings drive demand for medicines, devices and clinical trials, influence regulatory decisions, and can materially affect a healthcare company’s revenue outlook.

anterior segment surgery medical

Surgery on the eye’s front structures—such as the cornea, iris, lens and surrounding tissues—performed to restore vision, remove disease, or correct deformities. Think of it as repairing the front porch and entryway of a house so light can enter and the interior works properly. Investors care because procedure volume, device sales, implant demand and reimbursement policies directly affect revenue and growth potential for medical device makers, clinics and drug developers in ophthalmology.

vitreoretinal medical

Relating to the vitreous (the clear, gel-like substance filling the eye) and the retina (the light-sensitive layer at the back of the eye). Investors watch vitreoretinal treatments, devices and drugs because they target serious vision conditions; progress in clinical trials, approvals, or new surgical tools can change a medical company’s sales prospects and valuation much like a breakthrough engine or sensor can transform a carmaker’s market position.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/07/2026 - 07:00 AM

Increased cutting speed of 25,000 cuts per minute¹ is designed to minimize retinal traction,² increase vitreous flow¹ and reduce infusion pressure fluctuations when used with Adaptive Fluidics.^3*
Bi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade^®.^1*†
The resulting stability, efficiency and control help boost confidence for retina surgeons to deliver exceptional patient outcomes.

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite^®Vision Enhancement System.

“The launch of Bi-Blade+ is the latest example of our commitment to delivering meaningful innovation in Europe,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “Stellaris Elite has long been relied upon by European surgeons, and the 2024 Adaptive Fluidics software upgrade further enhanced the precise control and efficiency of the platform. We’re confident that the addition of Bi-Blade+ will also deliver meaningful benefits to retina surgeons and their patients.”

Bi-Blade+ provides an increased flow rate of 25%, enabling more efficient vitreous removal compared to Bi-Blade.^1* At maximum speed, Bi-Blade+ also demonstrates a 62% reduction in cutter vibration compared to Bi-Blade, offering the surgeon optimized feel and comfort toward a stable surgical experience.⁴

Adaptive Fluidics automates fluid infusion to the eye in response to real-time vacuum commands from the surgeon, delivering precise and responsive fluidics infusion at every step of a vitrectomy procedure.

These two technologies combine to support and maintain IOP stability and control. When combined with Adaptive Fluidics, Bi-Blade+ demonstrated a 62% reduction in average infusion pressure compared to surgeries in which Adaptive Fluidics was not used.³ Continuous aspiration also provides consistent intraocular pressure (IOP) stability.^3* In one study, use of Bi-Blade+ with Adaptive Fluidics resulted in a significant improvement in chamber IOP at a range closer to physiologic IOP (10 – 20 mmHg) even during high vacuum levels.^3**

“The higher cut rate of Bi-Blade+ offers a significant advantage when removing vitreous,” said Professor Marco Mura, MD, University of Ferrara, Ferrara, Italy. “The ability to increase flow rate while maintaining a small sphere of influence and calm environment means surgeons can have more confidence when working close to the retina.”

*Based on ex vivo and in vitro testing.

**Based on ex vivo and in vitro testing comparing original Bi-Blade to single-port cutter.

^†Bi-Blade^® is a trademark of Medical Instrument Development Laboratories, Inc. and is used by Bausch + Lomb under license.

Bi-Blade™+ Indications and Important Safety Information

Indications and Intended Use: The Bausch + Lomb vitrectomy cutter pouches are intended to cut and remove vitreous from the eye. They are indicated for any ocular condition requiring anterior vitrectomy during anterior segment surgery and for any vitreoretinal condition requiring vitrectomy during posterior or combined surgery.

Compatible Equipment: Stellaris Elite Bi-Blade+ accessories are only intended to operate with Bausch + Lomb Stellaris Elite vision enhancement systems with Bi-Blade+ procedure pack compatibility.

Known residual risks and complications include but are not limited to: infection; inflammation; ocular damage; trauma; cataract formation (not applicable in cataract removal procedures); foreign body/particulates in eye; intraocular pressure (IOP) variance that may cause damage to patient’s eye; visual impairment; ischemia; allergic reaction; edema.

ATTENTION: See the Instructions for Use for detailed directions, proper use, and full risk and safety information.

CAUTION: Federal (U.S.) Law restricts this device to sale, by or on the order of a physician.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Forward-looking Statements

This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements may generally be identified by the use of the words “anticipates,” “seeks,” “expects,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “potential,” “pending” or “proposed” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

Heuer R, Papour A, Higgins G. Vitrectomy flow performance and optimized system settings for retina shaving with 25g, 25,000cpm dual-action vitrectomy probes. Poster presented at: ARVO conference; May 2025; Salt Lake City, UT.
Higgins G, Papour A. Comparison of traction, sphere of influence, and pulsatile flow in-vitro vitrectomy using 25 ga 25,000 CPM dual action vitrectomy probes and 25ga 7,500 CPM single action vitrectomy probes. Poster presented at: ARVO conference; May 2025; Salt Lake City, UT.
Papour A, Hosten L. Intraocular pressure (IOP) optimized performance settings with posterior adaptive fluidics (PAF), and 25 gauge 25,000 cpm dual-action vitrectomy cutters. Invest Ophthalmol Vis Sci. 2024;65(7). Association for Research in Vision and Ophthalmology 2024 abstract 914.
Data on file.

BBL.0008.USA.26